Abivax SA reports developments as a clinical-stage biotechnology company developing therapeutics that modulate immune response in chronic inflammatory diseases. Its news centers on obefazimod (ABX464), the company’s lead therapeutic candidate, including clinical and preclinical data in inflammatory bowel disease, Phase 3 ABTECT work in moderately to severely active ulcerative colitis, and related safety, efficacy, biomarker, and patient-reported outcome analyses.
Recurring updates also cover financial results, annual and regulatory reporting in France and the United States, American Depositary Share offerings, royalty certificate obligations, public-company governance, annual meeting materials, and trading references for its Euronext Paris and Nasdaq-listed securities.
Abivax SA (ABVX) provided an update on its key clinical programs and leadership changes. The Phase 3 ABTECT trial for obefazimod in ulcerative colitis is on track to complete enrollment in early Q1 2025, with top-line results expected in early Q2 2025. The company is making progress on its pre-clinical combination therapy program. Sylvie Grégoire has been named Chair of Abivax's Board of Directors, while Dr. Fabio Cataldi and Dr. David Zhang have been appointed as Chief Medical Officer and Chief Strategy Officer, respectively.
Abivax's cash position allows for runway into Q4 2025, covering the ABTECT 8-week induction top-line results. The company is focusing on R&D while streamlining G&A expenses. The Phase 2b ENHANCE-CD trial for Crohn's disease is planned to start enrollment in September 2024.
Abivax SA, a clinical-stage biotechnology company, announced the results of its Ordinary and Extraordinary General Meeting held on May 30, 2024.
The shareholders approved all resolutions proposed by the Board, including the financial statements for 2023, the compensation policy for top executives, and delegations related to financial transactions.
New Board members, Mr. Troy Ignelzi, Dr. June Lee, and Ms. Camilla Soenderby, were ratified.
Details of the vote results can be accessed on the company's website.
Summary not available.
Summary not available.
Summary not available.